Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples